The Technical AnalystExchange: HKSE Sector: Pharmaceuticals Industry: Drug Manufacturers—General
United Laboratories Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.05% HKD9.60
America/New_York / 3 mai 2024 @ 04:08
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 17 443 mill |
| EPS: | 1.610 |
| P/E: | 5.96 |
| Earnings Date: | Mar 26, 2024 |
| SharesOutstanding: | 1 817.03 mill |
| Avg Daily Volume: | 3.93 mill |
| RATING 2024-05-03 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.25x |
| Company: PE 5.96 | sector: PE 23.82 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.36x |
| Company: PE 5.96 | industry: PE 16.59 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
HKD22.60 (135.44%) HKD13.00 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
HKD 9.17 - 10.03 ( +/- 4.47%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | HKD9.60 (1.05% ) |
| Volume | 2.17 mill |
| Avg. Vol. | 3.93 mill |
| % of Avg. Vol | 55.30 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 3933.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
3933.HK
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.